Takeda Pharmaceutical Company Limited (TAK) trades at a trailing P/E of 81.4, forward P/E of 0.3. Trailing earnings yield is 1.23%, forward earnings yield 322.58%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $2,790.01.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 50.2 | -0.24 | 2.07 | 2.23 | 3.51% |
| 2017 | 35.8 | 0.82 | 2.17 | 2.37 | 3.45% |
| 2018 | 21.7 | 0.35 | 2.03 | 2.29 | 3.50% |
| 2019 | 40.2 | -0.57 | 0.85 | 2.09 | 3.26% |
| 2020 | 114.9 | -1.94 | 1.08 | 1.54 | 5.56% |
| 2021 | 16.8 | 0.02 | 1.22 | 1.97 | 4.49% |
| 2022 | 23.7 | -0.61 | 0.96 | 1.53 | 5.21% |
| 2023 | 21.4 | 0.55 | 1.07 | 1.69 | 4.12% |
| 2024 | 45.0 | -0.82 | 0.89 | 1.52 | 4.43% |
| 2025 | 66.3 | -2.57 | 1.03 | 1.56 | 4.23% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2015 | $50.86 | $1.81T | $80.17B | 4.4% |
| 2016 | $73.13 | $1.73T | $114.94B | 6.6% |
| 2017 | $118.78 | $1.77T | $186.89B | 10.6% |
| 2018 | $34.78 | $2.1T | $109.13B | 5.2% |
| 2019 | $14.13 | $3.29T | $44.24B | 1.3% |
| 2020 | $119.48 | $3.2T | $376.01B | 11.8% |
| 2021 | $72.94 | $3.57T | $230.06B | 6.4% |
| 2022 | $100.97 | $4.03T | $317.02B | 7.9% |
| 2023 | $45.58 | $4.26T | $144.07B | 3.4% |
| 2024 | $33.62 | $4.58T | $107.93B | 2.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $57.54 | $56.08 – $59.00 | $4.65T | $4.47T – $4.75T | 1 |
| 2027 | $92.39 | $44.75 – $118.37 | $4.7T | $4.68T – $4.72T | 2 |
| 2028 | $107.19 | $101.92 – $110.39 | $4.75T | $4.57T – $4.86T | 1 |
| 2029 | $134.10 | $127.52 – $138.12 | $4.88T | $4.7T – $5T | 1 |
| 2030 | $163.54 | $155.51 – $168.43 | $5.04T | $4.84T – $5.15T | 1 |
